Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.71% | 9.19% | -149.04% | -44.00% | -316.50% |
| Total Depreciation and Amortization | -50.00% | 473.33% | 0.00% | 214.29% | 185.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 496.89% | -123.88% | 602.52% | -69.12% | -206.76% |
| Change in Net Operating Assets | -703.88% | -190.67% | -17.25% | 90.45% | -215.77% |
| Cash from Operations | -33.42% | -201.13% | -7.64% | -43.33% | -527.53% |
| Capital Expenditure | -- | 100.00% | 100.00% | 44.23% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 35.54% | -- | -- | -- |
| Cash from Investing | -- | 35.54% | 173,180.00% | 33,169.23% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 1,515.71% | -- | -99.95% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 408.49% | -- | -- | -- |
| Cash from Financing | -- | 8,667.32% | 110.76% | -99.97% | -- |
| Foreign Exchange rate Adjustments | 102.59% | 126.13% | -97.30% | 100.50% | -7,633.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.07% | 249.91% | 399.43% | -107.05% | -993.96% |